Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology
BOSTON--(BUSINESS WIRE)-- Sensible Biotechnologies, a biotechnology company pioneering a cell-based platform for the design and manufacturing of mRNA therapeutics, today announced an initiative to accelerate the development of next-generation mRNA medicines through AI-driven molecular design powered by NVIDIA accelerated computing and AI.
'By combining our cell-based platform with NVIDIA accelerated computing and AI, we're laying the foundation for programmable, high-performance RNA medicines.' Miroslav Gasparek, CEO and co-founder of Sensible Biotechnologies.
Sensible has developed a unique design, optimization, and manufacturing process for producing mRNA drugs within living cells. The mRNA platform, which can include a range of novel modifications, creates a pure and low-immunogenicity drug product, unlocking new therapeutic areas with safe, effective, affordable and repeatable mRNA therapeutics. This replaces traditional in vitro transcription methods, which are unable to meet the demands of next-generation therapies for cancer, rare diseases, gene editing, and other unmet medical needs.
To enable predictive and precise mRNA sequence design, Sensible's proprietary closed-loop AI-powered design and optimization platform models RNA folding from raw sequence to stable conformation. It integrates NVIDIA technology, including NVIDIA BioNeMo framework and NVIDIA NIM microservices on the NVIDIA DGX Cloud platform with NVIDIA Hopper GPUs, to apply physics-based simulations and machine learning to understand how RNA folds and behaves in complex biological environments.
Using DGX Cloud with NVIDIA H100 80 GB and double-precision performance, Sensible achieves over 11,000 simulation steps per second. This performance enables the team to screen multiple RNA candidates in parallel, reducing simulation runtimes from overnight to under an hour per sequence.
By incorporating NVIDIA technology, Sensible has cut its mRNA optimization cycles from 15 days to just one – a reduction of more than 90%. This efficiency enables faster iteration and informed sequence optimization, giving Sensible the ability to rapidly manipulate mRNA design space and advance the next generation of life-saving medicines.
'Producing therapeutic mRNA inside living cells requires solving intricate biological problems, from RNA folding to packaging,' said Krishna Motheramgari, PhD, Principal Computational Scientist at Sensible Biotechnologies. 'With advanced NVIDIA accelerated computing and AI, we can simulate these dynamics rapidly and accurately, accelerating our design cycle dramatically.'
'This technology integration brings us closer to our vision of rationally designed mRNA therapeutics,' said Miroslav Gasparek, Chief Executive Officer and co-founder of Sensible Biotechnologies. 'By combining our cell-based platform with NVIDIA accelerated computing and AI, we're laying the foundation for programmable, high-performance RNA medicines.'
About Sensible Biotechnologies, Inc.
Sensible Biotechnologies is developing the first cell-based platform for the design, optimization, and manufacturing of highly functional, low-immunogenic mRNA, unlocking the therapeutic potential of mRNA for pharma and biotech partners across a wide range of applications. Based in Boston, Oxford and Bratislava, Sensible has raised more than $13M from leading life science and deep tech investors, including Recode Ventures, BlueYard Capital, Kaya VC, Backed VC, Y Combinator, ZAKA VC, and Onsight – the VC fund founded by the co-founder of BioNTech, Christoph Huber, and the co-founder of ARM, Hermann Hauser.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
CoreWeave (CRWV) Jumps 8% on Rosy Growth Prospects
CoreWeave, Inc. (NASDAQ:CRWV) is one of the CoreWeave grew its share prices by 7.99 percent on Friday to hit a new all-time high, as investors continued to load up positions amid rosy growth prospects. At intraday trading, shares of CoreWeave, Inc. (NASDAQ:CRWV) jumped as high as 10 percent to hit $187, before paring gains to finish the day at $170, as investors appeared to have flocked to the booming Artificial Intelligence industry for safety to mitigate risks from the ongoing geopolitical tensions. In recent news, CoreWeave, Inc. (NASDAQ:CRWV) announced a record-breaking performance from using 2,496 of Nvidia Corp.'s latest Grace Blackwell Chips on its AI-optimized cloud platform, making its submission the largest-ever benchmarked under MLPerf. In March this year, CoreWeave, Inc. (NASDAQ:CRWV) bagged an $11.9-billion deal with OpenAI and welcomed it as a new investor through the sale of $350 million CRWV stocks to the latter. Last month, OpenAI upsized the deal with another $4 billion worth of contract. A close-up of a network administrator's hands working on a cloud computing server. Last month, it was tapped by Aston Martin Aramco as its official AI cloud computing partner, where it will provide AI-accelerated engineering opportunities to support car design efficiency. While we acknowledge the potential of CRWV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Nvidia (NVDA) Rises After Cathie Wood Rebuilds $18.5M Stake Near All-Time High
Cathie Wood's Ark Innovation ETF (ARKK, Financials) resumed its position in Nvidia (NVDA, Financials), purchasing 128,163 shares valued at approximately $18.5 million on June 16, as the stock trades just 2.7% below its all-time high of $149.41. The move marks a reversal from 2022, when Wood exited her Nvidia position amid tightening U.S. export controls and macroeconomic concerns. She began rebuilding the stake in April following eased trade tensions and the Trump administration's decision to roll back AI-related export restrictions. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The buy came shortly after Nvidia reported fiscal first-quarter results on May 28, with adjusted earnings of 96 cents per share on $44.06 billion in revenue, beating expectations of 93 cents and $43.31 billion, respectively. For the July quarter, the company forecast $45 billion in revenue, nearly $1 billion below consensus estimates, citing the impact of chip restrictions to China. Nvidia said revenue would have been about $8 billion higher without those curbs. China accounted for 13% of the company's revenue in the past fiscal year. Despite geopolitical risks, Nvidia stock is up 8.3% year to date. Wood's purchase comes as Ark Innovation ETF gains momentum, rising 15.9% in 2025 through June 18, outpacing the S&P 500's 1.9% increase. Wood's strategy remains focused on innovation platforms such as artificial intelligence, robotics, and blockchain, with Nvidia seen as a core holding aligned with those themes. Her flagship fund, however, has faced volatility, including a 60% decline in 2022 and a five-year annualized return of negative 0.3%, compared with the S&P 500's 15.7%. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Nvidia Might Be Getting Into the Humanoid Robot Game. Should You Buy NVDA Stock Here?
Nvidia (NVDA) shares are in focus on Friday following reports the AI chip giant is venturing into a new frontier: humanoid robots. According to sources that spoke with Reuters on condition of anonymity, Foxconn is developing humanoid robots in collaboration with Nvidia, with plans of deploying them at its new Houston facility. Dear Tesla Stock Fans, Mark Your Calendars for June 30 The 'Golden Era' for Tesla Starts June 22. Should You Buy TSLA Stock First? Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! These machines will reportedly help assemble Nvidia's AI servers – marking the first time for one of its products to be built with assistance from humanoid robots. Nvidia stock remains near record levels, trading at about $144 at the time of writing. Nvidia's collaboration with Foxconn is significant for investors given it showcases demand for its Isaac robotics platform and Jetson AI chips. Additionally, the Reuters report signals NVDA's long-term potential in the trillion-dollar robotics economy. It reinforces that Nvidia will emerge as the foundational infrastructure layer as industries embrace automation over the next few years, making this venture strategically and financially meaningful for those invested in Nvidia stock. The humanoid robot news arrives only days after reports that NVDA plans on attending the China International Supply Chain Expo in July. Barclays analyst Tom O'Malley expects continued AI demand to help Nvidia beat estimates in the second half of 2025. Despite a slower-than-expected ramp in Blackwell chip production, O'Malley sees massive upside potential in the AI stock as utilization remains rather encouraging. Additionally, the company's next-generation 'Blackwell Ultra' remains on track and feedback from suppliers has also been positive for the remainder of this year, the analyst told clients in his latest report. Barclays reiterated its 'Overweight' rating on Nvidia shares on Friday and raised its price target to $200, indicating they could rally another 40% from current levels. While not as bullish as Barclays, other Wall Street firms remain constructive on Nvidia stock for the next 12 months as well. According to Barchart, the consensus rating on NVDA shares currently sits at 'Strong Buy' with the mean target of about $175 indicating potential upside of some 22% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
